Log in

NASDAQ:CTICCTI BioPharma Stock Price, Forecast & News

$1.18
+0.03 (+2.61 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.14
Now: $1.18
$1.18
50-Day Range
$1.01
MA: $1.12
$1.32
52-Week Range
$0.62
Now: $1.18
$1.93
Volume219,100 shs
Average Volume308,938 shs
Market Capitalization$86.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.53
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Read More
CTI BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.38 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTIC
Previous SymbolNASDAQ:CTICD
CUSIPN/A
Phone206-282-7100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.35 million
Book Value$0.31 per share

Profitability

Net Income$-40,020,000.00

Miscellaneous

Employees46
Market Cap$86.94 million
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive CTIC News and Ratings via Email

Sign-up to receive the latest news and ratings for CTIC and its competitors with MarketBeat's FREE daily newsletter.

CTI BioPharma (NASDAQ:CTIC) Frequently Asked Questions

How has CTI BioPharma's stock been impacted by COVID-19 (Coronavirus)?

CTI BioPharma's stock was trading at $0.8901 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CTIC shares have increased by 32.6% and is now trading at $1.18. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of CTI BioPharma?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CTI BioPharma in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CTI BioPharma.

When is CTI BioPharma's next earnings date?

CTI BioPharma is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for CTI BioPharma.

How were CTI BioPharma's earnings last quarter?

CTI BioPharma Corp (NASDAQ:CTIC) announced its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.13) by $0.07. View CTI BioPharma's earnings history.

When did CTI BioPharma's stock split? How did CTI BioPharma's stock split work?

CTI BioPharma shares reverse split on the morning of Tuesday, January 3rd 2017. The 1-10 reverse split was announced on Friday, December 9th 2016. The number of shares owned by shareholders was adjusted after the closing bell on Friday, December 30th 2016. An investor that had 100 shares of CTI BioPharma stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for CTIC?

2 equities research analysts have issued 12-month price objectives for CTI BioPharma's shares. Their forecasts range from $3.00 to $3.50. On average, they expect CTI BioPharma's share price to reach $3.25 in the next twelve months. This suggests a possible upside of 175.4% from the stock's current price. View analysts' price targets for CTI BioPharma.

Has CTI BioPharma been receiving favorable news coverage?

Press coverage about CTIC stock has trended somewhat negative recently, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. CTI BioPharma earned a media sentiment score of -1.3 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news about CTI BioPharma.

Who are some of CTI BioPharma's key competitors?

What other stocks do shareholders of CTI BioPharma own?

Who are CTI BioPharma's key executives?

CTI BioPharma's management team includes the following people:
  • Dr. Adam R. Craig, Pres, CEO, Interim Chief Medical Officer & Director (Age 53)
  • Dr. Jack W. Singer, Co-Founder & Consultant (Age 76)
  • Mr. David H. Kirske, Exec. VP, CFO & Sec. (Age 65)
  • Mr. Bruce J. Seeley, Exec. VP & COO (Age 55)
  • Mr. Ed Bell, Sr. Director of Investor Relations

What is CTI BioPharma's stock symbol?

CTI BioPharma trades on the NASDAQ under the ticker symbol "CTIC."

How do I buy shares of CTI BioPharma?

Shares of CTIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CTI BioPharma's stock price today?

One share of CTIC stock can currently be purchased for approximately $1.18.

How big of a company is CTI BioPharma?

CTI BioPharma has a market capitalization of $86.94 million and generates $3.35 million in revenue each year. CTI BioPharma employs 46 workers across the globe.

What is CTI BioPharma's official website?

The official website for CTI BioPharma is www.ctibiopharma.com.

How can I contact CTI BioPharma?

CTI BioPharma's mailing address is 3101 WESTERN AVENUE SUITE 800, SEATTLE WA, 98121. The biopharmaceutical company can be reached via phone at 206-282-7100 or via email at [email protected]

This page was last updated on 7/3/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.